Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL
Status:
Unknown status
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
Lymphoma is one of the fastest growing malignancies in the world, with an annual incidence
rate of about 4%. Non-Hodgkin's lymphoma (NHL) is highly heterogeneous and can be broadly
divided into two major categories, B-cell lymphoma and T/NK cell lymphoma. It is composed of
diseases of different pathological types and malignant degrees, and the prognosis is not the
same.The anti-PD-1 antibody may benefit patients with relapsed or refractory Hodgkin's
lymphoma. At the same time, in non-Hodgkin's lymphoma, PD1 antibodies also show promising
therapeutic prospects. We propose this research program, based on the previous research at
home and abroad, to further clarify the role of PD-1 monoclonal antibody combined with
chemotherapy in the treatment of relapsed and refractory NHL patients, evaluate its clinical
efficacy and safety, and explore The best treatment strategy for patients with relapsed and
refractory NHL in China.